Literature DB >> 15107605

Inhibition of Chk1 by activated PKB/Akt.

Frank W King1, Jennifer Skeen, Nissim Hay, Emma Shtivelman.   

Abstract

We have shown recently that DNA damage effector kinase Chk1 is phosphorylated in vitro by protein kinase B/Akt (PKB/Akt) on serine 280. Activation of Chk1 by DNA damage in vivo is suppressed in presence of activated PKB. In this study we show that Chk1 is phosphorylated by PKB in vivo, and that increased phosphorylation by PKB on serine 280 correlates with impairment of Chk1 activation by DNA damage. Our results indicate a likely mechanism for the negative effects that phosphorylation of serine 280 has on activation of Chk1. The Chk1 protein phosphorylated by PKB on serine 280 does not enter into protein complexes after replication arrest. Moreover, Chk1 phosphorylated by PKB fails to undergo activating phosphorylation on serine 345 by ATM/ATR. Phosphorylation by ATM/ATR and association with other checkpoint proteins are essential steps in activation of Chk1. Inhibition of these steps provides a plausible explanation for the observed attenuation of Chk1 activation by activated PKB after DNA damage.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15107605

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  29 in total

1.  Specific role of Chk1 phosphorylations in cell survival and checkpoint activation.

Authors:  Hiroyuki Niida; Yuko Katsuno; Birendranath Banerjee; M Prakash Hande; Makoto Nakanishi
Journal:  Mol Cell Biol       Date:  2007-01-22       Impact factor: 4.272

2.  Akt switches TopBP1 function from checkpoint activation to transcriptional regulation through phosphoserine binding-mediated oligomerization.

Authors:  Kang Liu; Joshua D Graves; Jessica D Scott; Rongbao Li; Weei-Chin Lin
Journal:  Mol Cell Biol       Date:  2013-09-30       Impact factor: 4.272

3.  Identification of WEE1 as a target to make AKT inhibition more effective in melanoma.

Authors:  Omer F Kuzu; Raghavendra Gowda; Arati Sharma; Mohammad A Noory; Gregory Kardos; SubbaRao V Madhunapantula; Joseph J Drabick; Gavin P Robertson
Journal:  Cancer Biol Ther       Date:  2017-11-30       Impact factor: 4.742

Review 4.  DNA damage accumulation and repair defects in acute myeloid leukemia: implications for pathogenesis, disease progression, and chemotherapy resistance.

Authors:  Maria Teresa Esposito; Chi Wai Eric So
Journal:  Chromosoma       Date:  2014-08-12       Impact factor: 4.316

5.  MDM2 is required for suppression of apoptosis by activated Akt1 in salivary acinar cells.

Authors:  Kirsten H Limesand; Kathryn L Schwertfeger; Steven M Anderson
Journal:  Mol Cell Biol       Date:  2006-09-18       Impact factor: 4.272

6.  Pim kinases phosphorylate Chk1 and regulate its functions in acute myeloid leukemia.

Authors:  L L Yuan; A S Green; S Bertoli; F Grimal; V Mansat-De Mas; C Dozier; J Tamburini; C Récher; C Didier; S Manenti
Journal:  Leukemia       Date:  2013-06-10       Impact factor: 11.528

7.  Wild-type RAS: keeping mutant RAS in CHK.

Authors:  Theonie Anastassiadis; Eric J Brown
Journal:  Cancer Cell       Date:  2014-02-10       Impact factor: 31.743

8.  Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response.

Authors:  Elda Grabocka; Yuliya Pylayeva-Gupta; Mathew J K Jones; Veronica Lubkov; Eyoel Yemanaberhan; Laura Taylor; Hao Hsuan Jeng; Dafna Bar-Sagi
Journal:  Cancer Cell       Date:  2014-02-10       Impact factor: 31.743

9.  Erbb2 suppresses DNA damage-induced checkpoint activation and UV-induced mouse skin tumorigenesis.

Authors:  Justin G Madson; David T Lynch; Jessica Svoboda; Rebecca Ophardt; Jodi Yanagida; Sumanth K Putta; Andrew Bowles; Carol S Trempus; Raymond W Tennant; Laura A Hansen
Journal:  Am J Pathol       Date:  2009-04-30       Impact factor: 4.307

Review 10.  Guanylyl cyclase C in colorectal cancer: susceptibility gene and potential therapeutic target.

Authors:  Jieru E Lin; Peng Li; Giovanni M Pitari; Stephanie Schulz; Scott A Waldman
Journal:  Future Oncol       Date:  2009-05       Impact factor: 3.404

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.